Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The export policy of all diagnostic kits and reagents (including instruments /apparatus) ... is being made free with immediate effect," the directorate general of foreign trade (DGFT) said in a notification
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Subscribe To Our Newsletter & Stay Updated
